469 related articles for article (PubMed ID: 27422055)
21. [Fertility preservation in women of the childbearing age: Indications and strategies].
Bénard J; Calvo J; Comtet M; Benoit A; Sifer C; Grynberg M
J Gynecol Obstet Biol Reprod (Paris); 2016 May; 45(5):424-44. PubMed ID: 27021926
[TBL] [Abstract][Full Text] [Related]
22. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
23. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.
Turner NH; Partridge A; Sanna G; Di Leo A; Biganzoli L
Ann Oncol; 2013 Sep; 24(9):2224-35. PubMed ID: 23709175
[TBL] [Abstract][Full Text] [Related]
24. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology.
Lambertini M; Cinquini M; Moschetti I; Peccatori FA; Anserini P; Valenzano Menada M; Tomirotti M; Del Mastro L
Eur J Cancer; 2017 Jan; 71():25-33. PubMed ID: 27940355
[TBL] [Abstract][Full Text] [Related]
25. Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study.
Lambertini M; Fontana V; Massarotti C; Poggio F; Dellepiane C; Iacono G; Abate A; Miglietta L; Ferreccio C; Pescio MC; Conte B; Blondeaux E; Bighin C; D'Alonzo A; Vaglica M; Zanardi E; Boccardo F; Ballestrero A; Anserini P; Del Mastro L
Breast; 2018 Oct; 41():51-56. PubMed ID: 30007268
[TBL] [Abstract][Full Text] [Related]
26. Conservative management of reproductive cancers. Ovarian protection during treatment.
Cui W; Phillips KA
Best Pract Res Clin Obstet Gynaecol; 2019 Feb; 55():49-58. PubMed ID: 30150091
[TBL] [Abstract][Full Text] [Related]
27. Advances in the Treatment and Prevention of Chemotherapy-Induced Ovarian Toxicity.
Cho HW; Lee S; Min KJ; Hong JH; Song JY; Lee JK; Lee NW; Kim T
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096794
[TBL] [Abstract][Full Text] [Related]
28. THERAPY OF ENDOCRINE DISEASE: Novel protection and treatment strategies for chemotherapy-associated ovarian damage.
Xiong J; Xue L; Li Y; Tang W; Chen D; Zhang J; Dai J; Zhou S; Lu Z; Wu M; Wang S
Eur J Endocrinol; 2021 May; 184(5):R177-R192. PubMed ID: 33630753
[TBL] [Abstract][Full Text] [Related]
29. Endocrine prevention of chemotherapy-induced ovarian failure.
Blumenfeld Z; Evron A
Curr Opin Obstet Gynecol; 2016 Aug; 28(4):223-9. PubMed ID: 27253235
[TBL] [Abstract][Full Text] [Related]
30. Fertility preservation in pediatric, adolescent and young adult female cancer patients.
Ayensu-Coker L; Bauman D; Lindheim SR; Breech L
Pediatr Endocrinol Rev; 2012 Nov; 10(1):174-87. PubMed ID: 23469394
[TBL] [Abstract][Full Text] [Related]
31. Fertility preservation options in breast cancer patients.
Kasum M; von Wolff M; Franulić D; Čehić E; Klepac-Pulanić T; Orešković S; Juras J
Gynecol Endocrinol; 2015; 31(11):846-51. PubMed ID: 26370157
[TBL] [Abstract][Full Text] [Related]
32. Infertility in reproductive-age female cancer survivors.
Levine JM; Kelvin JF; Quinn GP; Gracia CR
Cancer; 2015 May; 121(10):1532-9. PubMed ID: 25649243
[TBL] [Abstract][Full Text] [Related]
33. 'An ounce of prevention is worth a pound of cure': the case for and against GnRH-agonist for fertility preservation.
Blumenfeld Z; Katz G; Evron A
Ann Oncol; 2014 Sep; 25(9):1719-1728. PubMed ID: 24651411
[TBL] [Abstract][Full Text] [Related]
34. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
[TBL] [Abstract][Full Text] [Related]
35. [Preservation of fertility in women undergoing cytotoxic therapies].
Gris Martínez JM; Callejo Olmos J; Pérez Milán F
Med Clin (Barc); 2011 Dec; 137(15):702-7. PubMed ID: 21507439
[No Abstract] [Full Text] [Related]
36. Strategies for fertility preservation in young early breast cancer patients.
Tomasi-Cont N; Lambertini M; Hulsbosch S; Peccatori AF; Amant F
Breast; 2014 Oct; 23(5):503-10. PubMed ID: 24934638
[TBL] [Abstract][Full Text] [Related]
37. [Fertility preservation strategies in young women in case of breast cancer or hematologic malignancy].
Decanter C; Robin G
Gynecol Obstet Fertil; 2013 Oct; 41(10):597-600. PubMed ID: 24094596
[TBL] [Abstract][Full Text] [Related]
38. [Medical, legal and ethical aspects of fertility preservation in cancer survivor].
Záhumenský J; Kucera E; Kosová T; Zmrhal J; Stejskal M; Stejskal D
Ceska Gynekol; 2012 Apr; 77(2):163-6. PubMed ID: 22702076
[TBL] [Abstract][Full Text] [Related]
39. Fertility preservation and pregnancy outcome after malignancy.
Falcone T; Bedaiwy MA
Curr Opin Obstet Gynecol; 2005 Feb; 17(1):21-6. PubMed ID: 15711407
[TBL] [Abstract][Full Text] [Related]
40. [Fertility and fertility preservation in women].
Dittrich R; Lotz L
Dermatologie (Heidelb); 2023 Jul; 74(7):481-489. PubMed ID: 37289206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
